BIOMAT Database Logo BIOMAT Database Logo

Treatment of Parkinson's disease with novel dopamine D2 agonist SK&F 101468. 1989

R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.
January 1991, Pharmacology, biochemistry, and behavior,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
Ropinirole (SK and F 101468) in the treatment of Parkinson's disease.
October 1991, Journal of neurology, neurosurgery, and psychiatry,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist.
October 1989, British journal of clinical pharmacology,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
Neuroinhibitory effects of SK&F 85174, a novel dopamine receptor agonist.
January 1985, Journal of cardiovascular pharmacology,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
Autonomic and haemodynamic responses to SK & F 101468 (ropinirole), a DA2 agonist, in anaesthetised cats.
January 1990, European journal of pharmacology,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
Application of thermospray liquid chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry for the identification of cynomolgus monkey and human metabolites of SK & F 101468, a dopamine D2 receptor agonist.
July 1989, Journal of chromatography,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526.
May 1984, The Journal of pharmacology and experimental therapeutics,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
A novel dopamine agonist for the transdermal treatment of Parkinson's disease.
July 2005, Neurology,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
Early dopamine agonist treatment in Parkinson's disease.
January 1990, Advances in neurology,
R Kapoon, and Z Pirtosek, and J P Frankel, and G M Stern, and A J Lees, and J M Bottomley, and N S Haran
Dual dopamine agonist treatment in Parkinson's disease.
July 2003, Journal of neurology,
Copied contents to your clipboard!